About
About
HiFiBiO Therapeutics is an emerging clinical stage multinational company mobilizing the human immune system to treat cancer and autoimmune diseases.
Our Vision
Pioneer curative immunotherapies for each and every patient
Our Mission
Unlock the curative powers of the immune system with innovative biotherapeutics to improve patient lives
Our Strategy
Advance a sustainable pipeline of breakthrough immunotherapies through single cell driven Drug Intelligence Science (DIS®)
Our Team
Leadership Team
Michael Croft, PhD
Director of Scientific Affairs, Professor and Head of the Division of Immune Regulation at La Jolla Institute for Immunology
Leslie Kean, MD, PhD
Director of the Stem Cell Transplantation Program and Physician at Dana-Farber/Boston Children’s Cancer Center and Blood Disorders Center
Aurélien Marabelle, MD, PhD
Senior Medical Oncologist in the Drug Development Department and the Clinical Director of the Cancer Immunotherapy Program at Gustave Roussy
Wendye Robbins, MD
Member Board of Trustees (Buck Institute for Research on Aging), Member Board of Directors (Rapt Therapeutics), Member Board of Directors (California Life Sciences Association)
Sebastian Amigorena, PhD
Director of the INSERM Immunity and Cancer Lab, and head of the Immunology and Immunotherapy department at Institut Curie.
Andrew Griffiths, PhD
Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris
David Weitz, PhD
Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University
Bradley Bernstein, MD, PhD
Director of Gene Regulation Observatory at the Broad Institute of MIT and Harvard
Jérôme Bibette, PhD
Professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI)
Robert Nicol, PhD
Venture Partner at RA Capital Management
Our Investors
We are funded by leading VC firms focused on transforming patient care including Mirae Asset, B Capital Group, IDG Capital, Kite Pharma, Sequoia Capital, LYFE Capital, etc
Open-Innovation Partnerships
We continue to establish strategic partnerships with leading pharmaceutical and biotechnology companies, as well as academic institutions to help allocate resources more efficiently, expand DIS® applications and accelerate pipeline commercialization. All our collaborations are architected for speed and driven by our scientific strategy.